On Friday, Zydus Life sciences Ltd announced that it had acquired rights to market MonoFerric (iron isomaltose) injection, used to treat iron deficiency among adult patients, in Nepal and India from Denmark-based Pharmacosmos A/S.

A regulatory filing company stated that when oral iron preparations are ineffective or cannot be used, or there is a clinical need to deliver iron critically, the MonoFerric can be used to treat iron deficiency. The financial details of the transaction have not been disclosed by Zydus Lifesciences yet. Dr Sharvil Pate, Managing Director of Zydus Lifesciences, said that Iron Deficiency is a severe healthcare challenge that also impacts the quality of life more in CKD (chronic kidney disease) patients.

Patients needing critical therapy would get access to the company’s enhanced. MonoFerric is available in more than 30 countries, including Europe and the US; over 28 million doses have been registered since the launch.

Founded by Ramanbhai Patel in 1952, Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) is a multinational pharmaceutical firm. Headquartered in Ahmedabad, it is engaged in the manufacture of generic drugs. The company is widely known for developing a Covid-19 vaccine named ZyCoV-D. The company ranked 100th on the Fortune India 500 list in 2022.